27 results about "Diethyl fumarate" patented technology

The invention discloses a lithium titanate battery, and relates to the technical field of batteries. The battery comprises a positive electrode, a negative electrode, an electrolyte and a diaphragm, and an addition product synthesized by dimethyl fumarate and benzidine according to a specific molar ratio is added into the electrolyte as a viscosity modifier, so that the viscosity increasing trend of the electrolyte at a low temperature is effectively reduced, and the migration rate of lithium ions is improved. And the electrolyte also comprises a lithium salt, an organic solvent and an auxiliary additive, so that the low-temperature performance and the cycling stability of the battery are favorably optimized. A positive active material is one or more of lithium iron phosphate, lithium manganate, lithium cobalt oxide or nickel manganese cobalt ternary materials, a negative active material is lithium titanate, and additives such as lithium nitrate and fluoroethylene carbonate are further combined, so that the capacity retention ratio and the charge-discharge efficiency of the battery in an extreme low-temperature environment of-40 DEG C are remarkably improved. The lithium titanate battery provided by the invention has excellent low-temperature adaptability, safety and long cycle life, and is applicable to power batteries and energy storage systems in alpine regions.

The present disclosure provides methods of treating multiple sclerosis (MS) using Compound 1 represented by the following structure, or a pharmaceutically acceptable salt thereof, in combination with dihydroxymethyl fumarate (DRF).

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The invention discloses application of dimethyl fumarate in preparation of a medicine for treating depression, and relates to the technical field of medicine research and development. Comprising experimental verification and medicine preparation, and the medicine preparation comprises the following steps: raw material preparation: weighing a dimethyl fumarate raw material and a medicinal carrier in proportion; uniformly mixing: fully mixing the dimethyl fumarate and the medicinal carrier by using a three-dimensional mixer or a double-cone mixer; granulating: adding a wetting agent for fluidized bed granulation or wet granulation to form granules with set sizes; granulating and drying: granulating the wet granules, drying, and controlling the water content of the granules; forming is conducted; and packaging: packaging the prepared medicine, and labeling information. The dimethyl fumarate is applied to the field of depression treatment, experiments verify that the dimethyl fumarate has a remarkable improvement effect on depression-like behaviors induced by chronic social contusion stress, and a new direction is provided for development of anti-depression drugs.

The present invention provides a method for synthesizing dimethyl fumarate and dimethyl maleate by dicarbonylation of acetylene, which uses acetylene, carbon monoxide and methyl nitrite as raw materials, and reacts them under the action of a supported palladium catalyst at a temperature of 60-200°C. o C. Under conditions of pressure of 0.1 to 6 MPa, acetylene is subjected to a double carbonylation reaction for 0.5 to 48 hours to obtain dimethyl fumarate and dimethyl maleate compounds. The present invention replaces methanol with methyl nitrite and employs a supported palladium catalyst, eliminating the need for any auxiliary agents and the direct use of O2. This avoids the problems of explosion limits, the use of corrosive auxiliary agents, and the separation and recycling of catalysts in the current double carbonylation of acetylene, overcoming the technical pain points of the prior art. Furthermore, the reaction has the advantages of high atomic utilization, mild reaction conditions, and high product yields. The byproduct, NO, can be recycled, making it suitable for industrial production and promising broad application prospects.

The invention provides a thermal expansion material, a resin liquid bridge plug and a deep shale gas shaft pressure-bearing plugging method. The thermal expansion material comprises a combination of any two or three of oxidative polymerization grafted 3-alkylthiophene modified thermal expansion microspheres, glycidyl methacrylate grafted modified thermal expansion microspheres and cinnamyl nitrile and diethyl fumarate cross-linked thermal expansion core-shell microspheres; by taking the total weight of the thermal expansion material as 100%, when the thermal expansion material comprises an oxidative polymerization grafted 3-alkylthiophene modified thermal expansion microsphere, a glycidyl methacrylate grafted modified thermal expansion microsphere and a cinnamyl nitrile and diethyl fumarate cross-linked thermal expansion core-shell microsphere, the contents of the three are respectively 15-55%, 25-75% and 30-65%. The thermal expansion material has good compatibility with resin liquid bridge plugs, can be uniformly dispersed in resin, does not agglomerate or settle, and can effectively inhibit the shrinkage of the resin through heat release expansion after solidification.

The application provides a polyester resin containing photoreactive dopamine and a preparation method and application thereof.The polyester resin containing photoreactive dopamine provided by the application is prepared from raw materials including dopamine methacrylamide (DMA), polypropylene fumarate (PPF), diethyl fumarate (DEF) and a photoinitiator.The dopamine molecules are integrated into the PPF crosslinking network structure through DMA, and the hydrophilicity of the material surface is significantly improved.The unsaturated polyester resin provided by the application can be applied to 3D printing technology based on face projection microstereolithography (PmuSL), the solidification forming process is simple, the three-dimensional structure is not limited, the application range is wide, and the final formed product can be used for further loading of bioactive substances, and has a wide application prospect in bone tissue engineering.The application further provides a preparation method and application of the polyester resin containing photoreactive dopamine.

Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.

The invention discloses an application of a small molecule compound covalently bound with GSDMD in preparation of a pyroptosis inhibitor. Through deep research, a novel compound AF-966 / 00547018, called C6 for short, which can specifically target GSDMD protein and effectively inhibit the pore-forming activity of the GSDMD protein is screened, and the structure of the compound AF-966 / 00547018 is shown in the specification. Compared with reported pyroptosis inhibitors such as disulfiram, dimethyl fumarate and Necrosulfenamide (NSA), the C6 shows higher activity of inhibiting the pyroptosis of the cells, and the C6 shows higher activity of inhibiting the pyroptosis of the cells.

The invention relates to the technical field of medicines, in particular to application of dimethyl fumarate in promoting proliferation of amniotic fluid stem cells and application of dimethyl fumarate in promoting proliferation of amniotic fluid stem cells. The invention discloses an application of dimethyl fumarate as an NRF2 expression promoter. The administration concentration of the dimethyl fumarate is 2.5 to 10 M; the dimethyl fumarate promotes NRF2 expression, protects the amniotic fluid stem cells, reduces oxidative damage and accelerates proliferation of the amniotic fluid stem cells, the cell culture time is shortened to 72 hours, and the DMF monovalent value is 1 / 40 of that of a growth factor.

The invention discloses application of dimethyl fumarate in preparation of a medicine for preventing and / or treating skeletal muscle atrophy, and belongs to the field of medicine. It is proved for the first time that DMF can effectively relieve related symptoms of skeletal muscle atrophy caused by cancer cachexia, and a new thought is provided for treatment of skeletal muscle atrophy. The DMF can relieve skeletal muscle atrophy by reducing mitochondrial damage and improving mitochondrial homeostasis imbalance, and the potential mechanism of the DMF is possibly related to the regulation of HIF1alpha, mTOR and other pathways. In addition, DMF can improve cancer cachexia skeletal muscle atrophy and does not inhibit tumor growth, which indicates that DMF directly acts on skeletal muscle instead of tumor. Due to the common end characteristic of mitochondrial homeostasis imbalance and the like in amyotrophy caused by different causes (such as aging and drug toxicity), the adjusting effect of DMF on homeostasis in skeletal muscle can be expanded to be used for preventing and treating other types of amyotrophy, including amyotrophy caused by aging, glucocorticoid, chemotherapy drugs and the like. The invention provides an application basis for preventing and treating skeletal muscle atrophy by DMF.

The invention belongs to the field of drug activity, and particularly relates to application of dimethyl fumarate in preparation of alveolar cell regeneration drugs. The invention systematically evaluates the effect of dimethyl fumarate in the process of promoting pulmonary alveolar regeneration by constructing a pulmonary alveolar organ model and a bleomycin-induced lung injury mouse model. Research results show that dimethyl fumarate can significantly promote regeneration of alveolar epithelium AT2 cells, so that alveolar epithelium structure repair is accelerated.

The invention relates to the technical field of biological medicines, and provides an application of dimethyl fumarate targeted GSDME in preparation of an anti-aging medicine. Dimethyl fumarate relieves the aging process by inhibiting the activity of GSDME, and can be used for developing and preparing anti-aging drugs.

The application discloses a kind of detection methods of dimethyl fumarate in food, it is related to chemical detection analysis technical field, comprising the following steps: S1, based on standard solution sample configuration standard curve;S2, the formula of purifying tube is selected and three representative samples, and based on purification scheme, sample is purified;S3, set two standard curve concentration points, carry out multiple sample data acquisition;S4, to three samples are detected in parallel double sample, and the detection limit level of sample, 1 times quantification limit level, 2 times quantification limit level and 5 times quantification limit level are 6 parallel standard addition test, based on experimental data is verified.The application makes that the dosage of organic reagent is saved about 80%, operation time is saved about 75%, the addition of internal standard DMM effectively calibrates the influence that target DMF changes with time and matrix interference, guarantees the result accuracy, while operation process is simple, to reduce the requirement of laboratory to personnel operation skill.

Examination of a test sample to determine the succination level of test sample is described. Examination can be via protein hydrolysis in total succination determination or via enzymatic digestion of isolated proteins and determination of the presence or quantity of modified peptides. The methods can be utilized for determination of excessive succination of lymph system proteins, which can be utilized in prevention or early detection of autoimmune disorders. Methods can be utilized for test samples of subjects under treatment with dimethyl fumarate suffering from an autoimmune disorder. Methods can be utilized as a determination that treatment of the subject with DMF should be slowed or stopped.

The invention discloses 4-octyl ester fumaric acid as well as a preparation method and application thereof. According to the invention, a new member 4-octyl ester fumaric acid is added for the research of fumaric acid derivatives. The method comprises the following steps: dissolving maleic anhydride and n-caprylic alcohol in ethyl acetate, and reacting at 90-100 DEG C for 10-20 hours to synthesize 4-octyl fumaric acid. The anti-inflammatory effect of the novel derivative 4-octyl fumaric acid is stronger than that of dimethyl fumarate.

The application provides application of nanosilver combined with an NRF2 inducer in treatment of multiple myeloma. Specifically, the nanosilver and the NRF2 inducer are combined, and in-vivo and in-vitro experiments are combined to explore the effect of the combination of the nanosilver and the NRF2 inducer on the multiple myeloma, and it is found that application of the NRF2 inducer promotes the inhibitory effect of the nanosilver on the multiple myeloma. In the application, the combination of the nanosilver and dimethyl fumarate can significantly increase the expression level of intracellular ROS, so that the multiple myeloma cells are in an over-oxidative stress state, thereby promoting cell apoptosis, which can provide a new option for future treatment of the multiple myeloma.

This invention discloses an antibacterial spinning oil suitable for acetate fibers used in cigarette filters, comprising an emulsifier, mineral oil, water, and an antibacterial agent. Before phase inversion, it is a transparent water-in-oil liquid; after phase inversion, it becomes a white oil-in-water emulsion. Phase inversion occurs in water or water containing the antibacterial agent. The mass ratio of the spinning oil to the water used for phase inversion or water containing the antibacterial agent before phase inversion is (1–49):(99–51). The antibacterial agent is a commercially available water-soluble antibacterial agent, selected from one or more of the following: 4-chloro-3-cresol, dichlorophenoxychlorophenol, bromochlorobisphenol, benzyl chloroethylammonium, benzalkonium chloride, dodecyl dimethyl ethylphenoxyethyl ammonium bromide, guanidine and guanidine polymers, quaternary ammonium salts, silver ions, copper ions, sodium phenylpropionate, nifedipine, dimethyl fumarate, sorbic acid, and dehydroacetic acid. The concentration of the antibacterial agent in water is 0.1 wt%–100 wt%.

The application discloses a lithium titanate battery and relates to the technical field of batteries.The battery comprises a positive electrode, a negative electrode, an electrolyte and a diaphragm, wherein the electrolyte is added with an adduct synthesized from dimethyl fumarate and benzidine in a specific molar ratio as a viscosity regulator, which effectively reduces the viscosity growth trend of the electrolyte at low temperature and improves the migration rate of lithium ions.The electrolyte further comprises lithium salt, organic solvent and auxiliary additives, which are beneficial to optimizing the low-temperature performance and cycle stability of the battery.The positive electrode active material is one or more of lithium iron phosphate, lithium manganate, lithium cobaltate or nickel-manganese-cobalt ternary material, and the negative electrode active material is lithium titanate, which is further combined with additives such as lithium nitrate and fluoroethylene carbonate, so that the capacity retention rate and charge-discharge efficiency of the battery at an extreme low temperature environment of-40 DEG C are significantly improved.The lithium titanate battery provided by the application has excellent low-temperature adaptability, safety and long cycle life, and is suitable for high-cold-area power batteries and energy storage system applications.

The invention relates to a preparation method of cyclobutane tetracarboxylic dianhydride, and belongs to the technical field of organic synthesis. The method comprises the steps of photochemical reaction, acidification reaction and anhydridation reaction. In the photochemical reaction, dimethyl fumarate is refined and then added into deionized water, the photochemical reaction is carried out through a UV lamp tube, and cyclobutane tetramethyl tetraformate is generated; the acidification reaction comprises the following steps: adding tetramethyl cyclobutane tetraformate into a hydrochloric acid solution, and carrying out hydrolysis reaction to generate cyclobutane tetracarboxylic acid; the anhydride reaction comprises the following steps: adding acetic anhydride and a PVP (Polyvinyl Pyrrolidone) crystallization aid into cyclobutane tetracarboxylic acid, and carrying out anhydride reaction to generate cyclobutane tetracarboxylic dianhydride; finally, through operations such as crystallization, filtration and pulping, the product purity is improved; the PVP crystallization auxiliary agent is prepared from an N-vinyl pyrrolidone monomer, 4-vinyl benzocyclobutene, allylidene triphenylphosphine and azodiisobutyronitrile, and the PVP crystallization auxiliary agent is prepared from the N-vinyl pyrrolidone monomer, the 4-vinyl benzocyclobutene, the allylidene triphenylphosphine and the The cyclobutane tetracarboxylic dianhydride prepared by the method is high in purity and high in total yield, and can meet the requirements of industrial large-scale production.

Examination of a test sample to determine the presence or quantity of succination of proteins is described. Examination can be via protein hydrolysis in total succination determination or via enzymatic digestion of isolated proteins and determination of the presence or quantity of modified peptides. The methods can be utilized for determination of excessive succination of lymph system proteins, which can be utilized in prevention or early detection of lymphopenia. Methods can be utilized for test samples of subjects under treatment with dimethyl fumarate suffering from multiple sclerosis. Methods can be utilized as a determination that treatment of the subject with DMF should be slowed or stopped.

The present disclosure provides methods and compositions for improving cell viability, mitochondrial function and / or frataxin expression or treating Friedreich's ataxia (FRDA) comprising two or more of monomethyl fumarate (MMF) or a MMF prodrug such as dimethyl fumarate (DMF), nicotinamide (NAM), idebenone (IDB) and nitisinone (NTS).

The application provides a low-sensitization aspartic acid ester resin composite and a preparation process thereof, and relates to the technical field of aspartic acid resin. The aspartic acid ester resin composite comprises the following raw material components: (A) polyaspartic acid resin, (B) monoamine maleate adduct, and (C) diethyl fumarate and / or diethyl maleate, which accounts for no more than 0.5% of the weight of the aspartic acid ester resin composite. The aspartic acid ester resin composite has the characteristics that the weight percentage of diethyl fumarate and diethyl maleate is low, no sensitization is caused to human body, and the curing performance is close to that of the existing polyaspartic acid resin.

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.

The invention relates to the technical field of organic synthesis, in particular to a catalyst and application thereof in preparation of o-aminoanisole through hydrogenation, the catalyst adopts aluminum oxide as a carrier, the catalyst integrally has high active site density and excellent molecular transport performance, platinum and cobalt form a bimetallic synergistic system, and in the inactivation regeneration process, the catalyst has high catalytic activity and high catalytic activity. Dimethyl fumarate and azodiisobutyronitrile are introduced in the preparation process, an organic modified layer is formed on the surface of a carrier through the double-bond characteristic of dimethyl fumarate and azodiisobutyronitrile, and metal anchoring points are increased, so that metal nanoparticles are not easy to migrate and agglomerate in a high-temperature or regeneration environment; therefore, high dispersion is maintained, long-term stable operation can be realized even in an industrial reaction system with high space velocity or easy carbon deposition, the conversion rate of o-nitroanisole and the selectivity of o-aminoanisole are improved, and the product purity is high.

The present invention is applicable to the field of fine chemical technology and provides a method for preparing cyclobutanetetracarboxylic dianhydride, comprising: 50 The photodimerization reaction of dimethyl fumarate with a size of 150 to 300 μm is carried out under aqueous phase conditions to obtain a crude cyclobutane tetracarboxylic acid ester; the crude cyclobutane tetracarboxylic acid ester is subjected to an acidification treatment, the acidification treatment temperature is 100-110 ° C, the acidification end control temperature is 5 to 20 ° C, and the holding time is 0.5 to 2h to obtain cyclobutane tetracarboxylic acid; the cyclobutane tetracarboxylic acid is refluxed under the action of acetic anhydride. The present application is beneficial to the penetration of ultraviolet light by controlling the particle size of dimethyl fumarate, and obtains a crude cyclobutane tetracarboxylic acid ester with high conversion rate; and then utilizing the solubility difference, most of the by-product fumaric acid is removed during the acidification process; the acetic anhydride refluxes the cyclobutane tetracarboxylic acid ring, and further dissolves the residual by-products to obtain a high-purity cyclobutane tetracarboxylic dianhydride product.

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E) but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E) but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.